124 related articles for article (PubMed ID: 28476377)
21. Correlation of breast cancer axillary lymph node metastases with stem cell mutations.
Donovan CA; Pommier RF; Schillace R; O'Neill S; Muller P; Alabran JL; Hansen JE; Murphy JA; Naik AM; Vetto JT; Pommier SJ
JAMA Surg; 2013 Sep; 148(9):873-8. PubMed ID: 23884447
[TBL] [Abstract][Full Text] [Related]
22. The lymph node ratio as prognostic factor in node-positive breast cancer.
Voordeckers M; Vinh-Hung V; Van de Steene J; Lamote J; Storme G
Radiother Oncol; 2004 Mar; 70(3):225-30. PubMed ID: 15064006
[TBL] [Abstract][Full Text] [Related]
23. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes.
Truong PT; Berthelet E; Lee J; Kader HA; Olivotto IA
Cancer; 2005 May; 103(10):2006-14. PubMed ID: 15812825
[TBL] [Abstract][Full Text] [Related]
24. Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society.
Ahn SH; Kim HJ; Lee JW; Gong GY; Noh DY; Yang JH; Jung SS; Park HY
Breast Cancer Res Treat; 2011 Nov; 130(2):507-15. PubMed ID: 21858659
[TBL] [Abstract][Full Text] [Related]
25. Tumor and breast volume ratio as a predictive factor for axillary lymph node metastases in T1c ductal invasive breast cancer: prospective observational clinico-pathological study.
Martić K; Vlajčić Z; Rudman F; Lambaša S; Tomasović-Lončarić Č; Stanec Z
Jpn J Clin Oncol; 2011 Dec; 41(12):1322-6. PubMed ID: 22039579
[TBL] [Abstract][Full Text] [Related]
26. Micrometastatic node-positive breast cancer: long-term outcomes and identification of high-risk subsets in a large population-based series.
Truong PT; Lesperance M; Li KH; MacFarlane R; Speers CH; Chia S
Ann Surg Oncol; 2010 Aug; 17(8):2138-46. PubMed ID: 20151215
[TBL] [Abstract][Full Text] [Related]
27. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
[TBL] [Abstract][Full Text] [Related]
28. Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.
Descotes F; Riche B; Saez S; De Laroche G; Datchary J; Roy P; André J; Bobin JY
Clin Breast Cancer; 2008 Apr; 8(2):168-77. PubMed ID: 18621614
[TBL] [Abstract][Full Text] [Related]
29. The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast.
Broekhuizen LN; Wijsman JH; Peterse JL; Rutgers EJ
Eur J Surg Oncol; 2006 Jun; 32(5):502-6. PubMed ID: 16569492
[TBL] [Abstract][Full Text] [Related]
30. The Breast Tumor Strain Ratio Is a Predictive Parameter for Axillary Lymph Node Metastasis in Patients With Invasive Breast Cancer.
Kim JY; Shin JK; Lee SH
AJR Am J Roentgenol; 2015 Dec; 205(6):W630-8. PubMed ID: 26587952
[TBL] [Abstract][Full Text] [Related]
31. [Expressions of CD147 and matrix metalloproteinase-2 in breast cancer and their correlations to prognosis].
Zhou S; Liu C; Wu SM; Wu RL
Ai Zheng; 2005 Jul; 24(7):874-9. PubMed ID: 16004819
[TBL] [Abstract][Full Text] [Related]
32. [Lobular invasive breast cancer prognostic factors: About 940 patients].
Jauffret C; Houvenaeghel G; Classe JM; Garbay JR; Giard S; Charitansky H; Cohen M; Bélichard C; Faure C; Darai É; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Coutant C; Dravet F; Chauvet MP; Chéreau Ewald E; Penault-Llorca F; Goncalves A; Lambaudie É
Gynecol Obstet Fertil; 2015 Nov; 43(11):712-7. PubMed ID: 26482833
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
34. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M
Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207
[TBL] [Abstract][Full Text] [Related]
35. Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease.
Al-Hilli Z; Hieken TJ; Hoskin TL; Heins CN; Boughey JC
J Surg Oncol; 2015 Oct; 112(5):453-7. PubMed ID: 26345596
[TBL] [Abstract][Full Text] [Related]
36. The prognostic value of node status in different breast cancer subtypes.
Yang ZJ; Yu Y; Hou XW; Chi JR; Ge J; Wang X; Cao XC
Oncotarget; 2017 Jan; 8(3):4563-4571. PubMed ID: 27999188
[TBL] [Abstract][Full Text] [Related]
37. The use of onestep nucleic acid amplification (OSNA) and tumour related factors in the treatment of axillary breast cancer: A predictive model.
Banerjee SM; Williams NR; Davidson TI; El Sheikh S; Tran-Dang M; Davison S; Ghosh D; Keshtgar MR
Eur J Surg Oncol; 2016 May; 42(5):641-9. PubMed ID: 26979647
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic role of axillary lymph node dissection in patients with stage IV breast cancer: a population-based analysis.
Wu SG; Li FY; Chen Y; Sun JY; Lin HX; Lin Q; He ZY
J Cancer Res Clin Oncol; 2017 Mar; 143(3):467-474. PubMed ID: 27812853
[TBL] [Abstract][Full Text] [Related]
39. Comparison of invasive micropapillary and triple negative invasive ductal carcinoma of the breast.
Chen HL; Ding A
Breast; 2015 Dec; 24(6):723-31. PubMed ID: 26392199
[TBL] [Abstract][Full Text] [Related]
40. Lymph node ratio: a new feature for defining risk category of node-positive breast cancer patients.
Yang C; Liu F; Li S; Li W; Zhai L; Ren M; Li Y; Lang R; Fan Y; Zhang X; Fu L
Int J Surg Pathol; 2012 Dec; 20(6):546-54. PubMed ID: 22736300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
